Начало・Списък с акции・Pfizer

Pfizer

Отворен

СекторЗдравеопазване

25.36 1.2

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.71

Максимум

25.63

Ключови измерители
By Trading Economics
Приходи	4.3B 2.7B
Продажби	-3.1B 14B
P/E Средно за сектора	18.832 64.641
EPS	0.75
Дивидентна доходност	7.01
Марж на печалбата	18.656
Служители	75,000
EBITDA	4.3B 5B

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+13.95% upside

Дивиденти
By Acuity
Дивидентна доходност Средно за сектора	7.01% 2.31%
Следващи печалби	4.08.2026 г.
Следваща дата на дивидент	1.09.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-9.7B 140B
Предишно отваряне	24.16
Предишно затваряне	25.36

Настроения в новините

By Acuity

32%

68%

100 / 340 Класиране в Healthcare

Pfizer Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 23:46 ч. UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

31.07.2026 г., 23:06 ч. UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

30.07.2026 г., 23:26 ч. UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

29.07.2026 г., 23:16 ч. UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

28.07.2026 г., 23:26 ч. UTC

Pfizer Inc shares are lower in after-market hours, reversing an earlier gain. The stock remains above its 20-day moving average.

27.07.2026 г., 18:56 ч. UTC

Pfizer Inc is trading higher, driven by gains in the Pharmaceuticals sub-sector. Shares pulled back earlier in the session from a session high.

24.07.2026 г., 18:06 ч. UTC

Pfizer Inc. shares are lower today, reflecting broader market trends. Earlier, shares fell significantly before partially recovering amid declining crude oil prices.

23.07.2026 г., 09:41 ч. UTC

News

Pfizer Inc. shares are higher in pre-market trading following FDA acceptance of a Priority Review for TALZENNA in combination with XTANDI for prostate cancer.

22.07.2026 г., 23:02 ч. UTC

News

Pfizer Inc. shares are higher in after-market hours following the FDA's acceptance of a Priority Review for TALZENNA and XTANDI in prostate cancer treatment.

21.07.2026 г., 23:11 ч. UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

20.07.2026 г., 23:16 ч. UTC

Pfizer Inc shares are higher in after-market trading, maintaining above their 20-day moving average despite broader market pressures from rising treasury yields.

Сравнение с други в отрасъла

Ценова промяна

Pfizer Прогноза

Ценова цел

By TipRanks

13.95% нагоре

12-месечна прогноза

Среден 28.5 USD 13.95%

Висок 35 USD

Нисък 25 USD

Според 22 анализатори от Wall Street, предложили 12-месечна ценова цел за Pfizer през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

22 ratings

Купи

Задържане

Продай

Според 22 анализатори, дали борсови рейтинги на Pfizer през последните 3 месеца.

Настроение

By Acuity

100 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.